CN116531457A - Traditional Chinese medicine composition for treating chronic pharyngitis and application thereof - Google Patents
Traditional Chinese medicine composition for treating chronic pharyngitis and application thereof Download PDFInfo
- Publication number
- CN116531457A CN116531457A CN202310677251.2A CN202310677251A CN116531457A CN 116531457 A CN116531457 A CN 116531457A CN 202310677251 A CN202310677251 A CN 202310677251A CN 116531457 A CN116531457 A CN 116531457A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- root
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 201000007100 Pharyngitis Diseases 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 241000903946 Clematidis Species 0.000 claims abstract description 12
- 241000405414 Rehmannia Species 0.000 claims abstract description 11
- 241000239226 Scorpiones Species 0.000 claims abstract description 11
- 241000935235 Fritillaria meleagris Species 0.000 claims abstract description 10
- 235000004347 Perilla Nutrition 0.000 claims abstract description 10
- 241001522129 Pinellia Species 0.000 claims abstract description 10
- 241000931705 Cicada Species 0.000 claims abstract description 9
- 241001180876 Saposhnikovia Species 0.000 claims abstract description 9
- 235000019508 mustard seed Nutrition 0.000 claims abstract description 9
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 8
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 8
- 235000011477 liquorice Nutrition 0.000 claims abstract description 8
- 241001071917 Lithospermum Species 0.000 claims abstract description 3
- 244000124853 Perilla frutescens Species 0.000 claims abstract 3
- 239000006187 pill Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 241001106477 Paeoniaceae Species 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 244000236658 Paeonia lactiflora Species 0.000 claims description 4
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 31
- 229940079593 drug Drugs 0.000 abstract description 17
- 208000024891 symptom Diseases 0.000 abstract description 17
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 12
- 208000026435 phlegm Diseases 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 5
- 239000013256 coordination polymer Substances 0.000 abstract description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 3
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 210000003800 pharynx Anatomy 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 241000229722 Perilla <angiosperm> Species 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 6
- 229960004436 budesonide Drugs 0.000 description 6
- HUJXHFRXWWGYQH-UHFFFAOYSA-O sinapine Chemical compound COC1=CC(\C=C\C(=O)OCC[N+](C)(C)C)=CC(OC)=C1O HUJXHFRXWWGYQH-UHFFFAOYSA-O 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000220261 Sinapis Species 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- 241000522620 Scorpio Species 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000009490 scorpio Substances 0.000 description 4
- 206010013789 Dry throat Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 241000218158 Clematis Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001547125 Fritillaria thunbergii Species 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010061549 Sensation of foreign body Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000002795 scorpion venom Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating chronic pharyngitis and application thereof. The traditional Chinese medicine composition comprises the following components in parts by mass: 14-16 parts of thunberg fritillary bulb, 8-10 parts of scorpion, 9-11 parts of radix clematidis, 14-16 parts of stir-fried mustard seed, 9-11 parts of cicada slough, 9-11 parts of lithospermum, 19-21 parts of rehmannia root, 19-21 parts of stir-fried white paeony root, 14-16 parts of perilla leaf, 9-11 parts of purified pinellia tuber, 9-11 parts of divaricate saposhnikovia root and 9-11 parts of liquorice. The traditional Chinese medicine composition can be used for preparing medicines for treating or relieving chronic pharyngitis, is superior to Western medicine control groups in clinical curative effect on treating qi depression and phlegm obstruction type CP, can obviously relieve clinical symptoms of patients, reduces TNF-alpha and IL-6 levels to a certain extent, can relieve inflammatory reaction of organisms, has good clinical application value, and is worthy of clinical popularization.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating chronic pharyngitis and application thereof.
Background
Chronic pharyngitis (Chronic Pharyngitis, CP), known as "chronic pharyngitis" in traditional Chinese medicine, is mainly characterized by chronic inflammation, mainly manifested by pharyngeal pain, and a long-lasting course of disease. The CP in China has higher morbidity, and because the chronic pharyngitis has longer disease course and is easy to repeat, the life and the quality of patients are seriously influenced, and the adverse reaction of western medicine treatment on the disease is more. The chronic pharyngitis is more harmful, and modern medicine mainly treats the chronic pharyngitis in a symptomatic way, and is effective in improving the pharyngeal symptoms of patients, but the etiology and pathogenesis of the chronic pharyngitis are not clear, so the treatment effect is poor.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating chronic pharyngitis and application thereof, and aims to solve the problems in the prior art in the background technology.
The invention is realized in such a way that a traditional Chinese medicine composition for treating chronic pharyngitis symptoms comprises the following components in parts by mass: 14-16 parts of thunberg fritillary bulb, 8-10 parts of scorpion, 9-11 parts of radix clematidis, 14-16 parts of stir-fried mustard seed, 9-11 parts of cicada slough, 9-11 parts of lithospermum, 19-21 parts of rehmannia root, 19-21 parts of stir-fried white paeony root, 14-16 parts of perilla leaf, 9-11 parts of purified pinellia tuber, 9-11 parts of divaricate saposhnikovia root and 9-11 parts of liquorice.
Preferably, the traditional Chinese medicine composition comprises the following components in parts by mass: 15 parts of fritillary bulb, 9 parts of scorpion, 10 parts of radix clematidis, 15 parts of fried mustard seed, 10 parts of cicada slough, 10 parts of herba lycopodii, 20 parts of rehmannia root, 20 parts of fried white peony root, 15 parts of perilla leaf, 10 parts of purified pinellia tuber, 10 parts of divaricate saposhnikovia root and 10 parts of liquorice.
The invention further discloses application of the traditional Chinese medicine composition in preparing medicines for treating or relieving chronic pharyngitis.
Preferably, the medicament also has a therapeutically effective amount of a traditional Chinese medicine composition and a pharmaceutically acceptable carrier thereof.
Preferably, the medicament is prepared into powder, pill, tablet, capsule, oral liquid, aerosol or injection.
In order to overcome the defects of the prior art, the invention discloses a traditional Chinese medicine composition for treating chronic pharyngitis and application thereof. The traditional Chinese medicine composition comprises the components of thunberg fritillary bulb, scorpion, radix clematidis, stir-fried mustard seed, cicada slough, herba lycopodii, rehmannia root, stir-fried white paeony root, perilla leaf, purified pinellia tuber, divaricate saposhnikovia root and liquorice; the fritillary bulb has bitter taste, cold property, lung and heart meridian return, and has the effects of clearing heat, resolving masses, relieving cough and reducing sputum, and researches show that the fritillary bulb mainly contains alkaloids, polysaccharides, total saponins, flavonoid components, volatile components and the like and has the effects of relieving pain, relieving cough, resisting inflammation, inhibiting bacteria, resisting cancer, resisting tumor and the like. The scorpion belongs to blood and meat products, has strong medicinal properties, is not easy to enter, is not hard to break, is not obtained by plants and ores, and has the powerful and fanciful effects in treating diseases. Clinical studies show that scorpion venom in scorpion can act on adrenergic nerves, effectively relax smooth muscle of bronchus, relieve bronchospasm, resist inflammation and the like. Zhejiang fritillary bulb is combined with scorpion, and both medicines have anti-inflammatory effect, and the two medicines are synergistic to relieve cough and inflammation and also relieve bronchospasm, and the two medicines are combined together into one powder to be used as monarch medicine, so that the curative effect is remarkable in the process of treating chronic pharyngitis.
Radix Clematidis, semen Sinapis Albae, periostracum Cicadae and herba Salviae chinensis are combined to remove meridian obstruction and pain, warm lung and eliminate phlegm, relieve sore throat and open voice, and dissipate stagnation and reduce swelling; xiang is pungent and salty in flavor, warm in nature, and enters bladder meridian for its actions of activating meridians and relieving pain. The stir-baked mustard is pungent in flavor and warm in nature, and has the actions of warming lung, eliminating phlegm and promoting qi circulation, and alleviating pungent and scattered channeling. Periostracum Cicadae is sweet in flavor and cold in nature, and has effects of dispelling wind-heat, relieving sore throat and opening voice. The stone is pungent and bitter in flavor and slightly cold in nature, and has the effects of clearing heat and promoting diuresis, and resolving masses and relieving swelling. Modern pharmacological researches show that clematis root has wide pharmacological activity, can play an anti-inflammatory and analgesic role by inhibiting inflammatory factors, inhibiting signal paths, inhibiting immunity and the like, and is often clinically combined with other traditional Chinese medicines, and the compatibility of stone can remove stasis and dissipate stagnation, detoxify and reduce swelling and relieve pain. The main chemical component of the fried sinapine is sinapine, and researches show that the sinapine has a definite asthma relieving effect and can relax airway smooth muscle. Modern pharmacological researches have shown that periostracum Cicadae has the effects of relieving inflammation, relieving cough, eliminating phlegm, relieving asthma, tranquilizing, relieving pain, relieving spasm, resisting convulsion, resisting coagulation, etc. The stir-fried mustard seed and cicada slough are combined in the recipe to achieve the effects of anti-inflammatory, asthma relieving and cough relieving. The four medicines are combined to serve as ministerial medicines and the cold and heat are mutually compatible, so that the effects of eliminating dampness and resolving phlegm without hurting yin are achieved, and meanwhile, the effects of removing blood stasis and resolving masses, detoxifying and relieving swelling and pain, anti-inflammatory and relieving asthma and cough are achieved.
Takes rehmannia root, stir-fried white peony root, purple perilla, purified pinellia tuber and divaricate saposhnikovia root as adjuvant drugs to play the roles of resolving phlegm and promoting qi, and has obvious curative effect on 'tangible excessive phlegm'; rehmannia root, radix rehmanniae is sweet and bitter in taste and cold in nature, and enters heart, liver and kidney, and has the effects of clearing heat and promoting fluid production. The stir-fried white paeony root has bitter, sour and slightly cold taste, has the effects of nourishing blood and astringing yin, and modern pharmacological researches show that the stir-fried white paeony root has the effects of easing pain, calming and resisting inflammation. Perillae herba She Weixin, with mild nature, and feasible qi flow, has antiinflammatory, antibacterial, antioxidant, antiallergic, antitumor, lipid synthesis regulating and controlling effects, and has outstanding antiinflammatory and antibacterial effects, and also has effects in relieving cough and asthma. The purified pinellia tuber is pungent and warm, enters spleen, stomach and lung meridians, and has the effects of drying dampness and resolving phlegm, and relieving swelling and pain. The traditional Chinese medicine composition has the effects of preventing flavor, being sweet and slightly warm in nature, dispelling wind and relieving exterior syndrome, is a 'lubricant in wind medicine', can be widely applied to treat various wind syndromes, whether external wind or internal wind, wind-cold or wind-heat, can be used together with the syndromes, and is commonly used for treating apoplexy, typhoid fever, pharyngitis and other syndromes with the effects of dispelling wind and relieving spasm, eliminating dampness and relieving pain, rising middle-jiao and yang, rising and dissipating fire. The medicines are combined together to be used as adjuvant medicines, wherein rehmannia root, stir-fried white paeony root and perilla leaf all have anti-inflammatory effect, and the three medicines cooperate to ensure that the anti-inflammatory effect is more remarkable. Glycyrrhrizae radix is used for regulating the functions of the other drugs. The cold and heat of the whole formula are combined and used together to achieve the effects of promoting qi circulation, resolving stagnation, resolving phlegm and resolving masses.
The traditional Chinese medicine composition is used for preparing medicines for treating or relieving chronic pharyngitis, the medicines comprise a therapeutically effective amount of the traditional Chinese medicine composition and a pharmaceutically acceptable carrier thereof, and the medicines are prepared into powder, pills, tablets, capsules, oral liquid, aerosol or injection. For example, the oral liquid is in the form of a Chinese medicinal preparation, and is obtained by decocting the Chinese medicinal composition in water; the pill can be obtained by conventional preparation techniques such as cleaning, air drying, pulverizing, drawing, shaping, selecting cover, and drying.
Compared with the defects and shortcomings of the prior art, the invention has the following beneficial effects: the invention improves the pharyngeal symptoms and respiratory tract symptoms of two groups of patients with chronic pharyngitis, treats qi depression and phlegm obstruction type CP, has better clinical curative effect than Western medicine control group, can obviously lighten the clinical symptoms of the patients, reduces the levels of TNF-alpha and IL-6 to a certain extent, can ease the inflammatory reaction of organisms, has good clinical application value and is worthy of clinical popularization.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
Examples
(1) Cleaning Bulbus Fritillariae Thunbergii, scorpio, radix Clematidis, semen Sinapis Albae preparata, periostracum Cicadae, herba Salviae chinensis, radix rehmanniae, radix Paeoniae alba preparata, folium Perillae, rhizoma Pinelliae preparata, radix Saposhnikoviae, and Glycyrrhrizae radix with clear water, and air drying respectively;
(2) 15g of thunberg fritillary bulb, 9 g of scorpion, 10 g of radix clematidis, 15g of stir-fried mustard seed, 10 g of cicada slough, 10 g of herba lycopodii, 20 g of rehmannia root, 20 g of stir-fried white paeony root, 15g of perilla leaf, 10 g of purified pinellia tuber, 10 g of divaricate saposhnikovia root and 10 g of liquorice are mixed, crushed into 160 meshes of powder, processed by a water pill processing technology, and prepared into water pills with the diameter of 4 mm granules, sterilized and packaged according to the measurement of 5 g/bag.
Examples
(1) Cleaning Bulbus Fritillariae Thunbergii, scorpio, radix Clematidis, semen Sinapis Albae preparata, periostracum Cicadae, herba Salviae chinensis, radix rehmanniae, radix Paeoniae alba preparata, folium Perillae, rhizoma Pinelliae preparata, radix Saposhnikoviae, and Glycyrrhrizae radix with clear water, and air drying respectively;
(2) Mixing Bulbus Fritillariae Thunbergii 16g, scorpio 11g, radix Clematidis 11g, semen Sinapis Albae 16g, periostracum Cicadae 11g, herba Salviae chinensis 11g, rehmanniae radix 21g, radix Paeoniae alba 21g, folium Perillae 16g, rhizoma Pinelliae Preparata 11g, radix Saposhnikoviae 11g, and Glycyrrhrizae radix 9 g, pulverizing into 160 mesh powder, making into watered pill with diameter of 4 mm, sterilizing, and packaging according to 5 g/bag.
Examples
(1) Cleaning Bulbus Fritillariae Thunbergii, scorpio, radix Clematidis, semen Sinapis Albae preparata, periostracum Cicadae, herba Salviae chinensis, radix rehmanniae, radix Paeoniae alba preparata, folium Perillae, rhizoma Pinelliae preparata, radix Saposhnikoviae, and Glycyrrhrizae radix with clear water, and air drying respectively;
(2) 14g of thunberg fritillary bulb, 8 g of scorpion, 9 g of clematis root, 14g of stir-fried mustard seed, 9 g of cicada slough, 9 g of herba lycopodii, 19 g of rehmannia root, 19 g of stir-fried white peony root, 14g of perilla leaf, 9 g of purified pinellia tuber, 9 g of divaricate saposhnikovia root and 11g of liquorice are mixed, and water is added for decoction for 2-3 hours to obtain oral liquid medicine.
Examples
1. Clinical data
1.1 general data
140 chronic pharyngitis patients who are collected and treated by the Ningxia traditional Chinese medicine hospital and the traditional Chinese medicine research institute in pulmonary disease department and the otorhinolaryngology department in the period from 9 months of 2021 to 3 months of 2023 are selected and all belong to qi depression and phlegm obstruction type as research objects.
The 140 patients selected were divided into a throat-arthralgia pill group (treatment group, i.e., water-paste pill prepared in example 1 for treatment, the same applies hereinafter) and a budesonide suspension (control group), 70 cases each, by the random number table method. 36 men and 34 women in the throat arthralgia pill group, wherein the average age (34.56+/-2.34) is 2-8 years, and the average course (6.24+/-1.35) is the same; the budesonide suspension group has 34 men and 36 women, the average age (35.13 +/-2.48) is 1-9 years old, the average course (6.36+/-1.25) is 6 years old, and the general data of the patient in the throat obstruction pill group (treatment group) and the budesonide suspension group (control group) are not different (P is more than 0.05), so that the budesonide suspension group has comparability. From the declaration of Helsinki [1] The research meets the ethical requirements.
1.2 diagnostic criteria
(1) Western medicine diagnosis and treatment Standard refers to the diagnosis and treatment guide for common diseases of ear-nose-throat department of traditional Chinese medicine [2] Standard of medium CP: the throat mucosa congestion is clinically manifested by dry throat, itching throat, cough, glowing throat pain and throat foreign body sensation, and the laryngoscope shows mucosa swelling or atrophy, has dark red color spot blocky dendritic congestion, swelling of the pharyngeal side and hyperplasia of the pharyngeal wall lymph follicles. (2) The diagnosis standard of the syndrome differentiation type of the chronic pharyngitis of the traditional Chinese medicine refers to the Chinese medical industry standard of the people's republic of China, the Chinese medical syndrome diagnosis curative effect standard [3] Advanced Chinese medicineTeaching materials of medicine institutions (science of ear nose and throat of traditional Chinese medicine) [4] And the "guidelines for clinical research of New Chinese medicine" issued by the national ministry of health in 1993 comprehensively formulate the standard of qi stagnation and phlegm obstruction type pharyngitis: dry throat, itching throat, feeling of foreign body, or with uncomfortable feeling, dysphoria, irritability, distension and fullness in chest and hypochondrium, singultus, central heating, poor appetite, restlessness, severe symptoms during emotion change, thin and greasy tongue fur, pale and fat or dark tongue, and wiry and slippery pulse.
1.3 inclusion criteria
(1) Meets the diagnosis standard of Chinese and Western medicine; (2) the age is 18-70 years old, and the course of disease is more than 3 months; (3) the patient informed consent and no other treatment was performed.
1.4 exclusion criteria
(1) Those who do not meet inclusion criteria; (2) patients with serious brain diseases or mental diseases cannot be treated in a matched manner or cannot be treated in a matched manner; (3) eliminating the complex syndrome of traditional Chinese medicine without major and minor division; (4) allergic to various medicines and can not cooperate with clinical observation of curative effects; (5) women in lactation or gestation.
2. Therapeutic method
Control group: the specific medicine is as follows: budesonide suspension for inhalation (specification (2 mL:1 mg) 30, trade name: promicifuge, manufactured by AstraZeneca Pty Ltd Enterprise, registration number: H20140475) was inhaled by aerosol, 1 inhalation each time, and the dose per inhalation was 1mg.
Treatment group: the specific medicine is as follows: the pill for treating pharyngitis is administered 6 g/time, 1 day and 2 times, half an hour after breakfast and supper, and 2 weeks in course.
Both groups can promote health of chronic pharyngitis, and avoid pungent and spicy food, smoking cessation and alcohol withdrawal. Both groups of treatment courses were 2 weeks.
3. Observation of curative effect
3.1, observe index
(1) Selecting serum albumin-6 and tumor necrosis factor-alpha as observation indexes, and detecting by adopting an ELISA method; (2) the scoring of the Chinese medical symptoms refers to the science of ear, nose and throat of Chinese medicine [5] Taking dry throat, burning sensation of pharynx, foreign body sensation of pharynx, itching throat, sore throat and cough as main symptoms, each item is classified into 3 grades: light, medium and heavy, each recorded 1, 2, 3, each fractionThe sum is the total symptom score, 18 score of full score, 0-6 score of light weight, 7-12 score of medium weight and 13-18 score of heavy weight.
3.2 standard of efficacy
Refer to the "diagnostic efficacy Standard of traditional Chinese medical Condition [3] Making and recovering: the symptoms are recovered to be normal, the signs are basically disappeared, the N is more than or equal to 90 percent, and the effect is obvious: the symptoms are close to normal, the signs are mostly disappeared, the N is less than or equal to 66.67 percent and less than or equal to 90 percent, and the effects are achieved: symptoms and signs are reduced before treatment, N is less than or equal to 33.33 percent and less than or equal to 66.67 percent, and the traditional Chinese medicine composition is ineffective: symptoms were not relieved, and N < 33.33%. N= [ (total pre-treatment fraction-total post-treatment fraction)/total pre-treatment fraction ] ×100%.
3.3 statistical methods
SPSS 25.0 for data processing and metering data±S) Representing, using t-test; the count data is expressed as a rate (%), using x 2 Checking; to be used forPA difference of < 0.05 is statistically significant.
3.4 treatment results
3.4.1, comparison of clinical efficacy of two groups
The total effective rate of the throat obstruction pill group (treatment group) is 92.86 percent (65/70), and the cure rate is 55.71 percent (39/70); the total effective rate of budesonide suspension (control group) is 74.23 percent (52/70), and the cure rate is 38.57 percent (27/70); two sets of comparisonsPAnd less than 0.05, the difference is statistically significant. The treatment effect of the treatment group is superior to that of the control group. See table 1.
3.4.2 comparison of inflammatory factor levels
Before treatment, IL-6 and TNF-alpha of two groups of patients are compared, and the difference has no statistical significance (P is more than 0.05); following treatment, both groups of patients had IL-6, TNF- α levels below pre-treatment (P < 0.05) and the treatment groups were below the control group (P < 0.05) as shown in Table 2.
Table 2 comparison of inflammatory factor levels before and after treatment for two groups of chronic pharyngitis patients (pg/ml,±S）
| group of | n | Time | Interleukin-6 | Tumor necrosis factor-alpha |
| Treatment group | 70 | Before treatment | 220.37±35.62 | 181.37±18.21 |
| After treatment | 141.65±13.21 △▲ | 100.21±11.36 △▲ | ||
| Control group | 70 | Before treatment | 219.52±37.53 | 185.45±19.34 |
| After treatment | 185.25±17.58 | 145.35±12.57 |
Note that: in comparison with the pre-treatment period of this group, △ p is less than 0.05; comparison with control group after treatment ▲ P＜0.05。
3.4.3, comparison of the integral improvement of two groups of symptoms
Symptoms of both groups of patients improved (P < 0.05) after treatment compared to before treatment; and the comparison of the score differences before and after the symptom treatment of the two groups of patients has statistical difference (P is less than 0.05), and the treatment effect of the treatment group is better than that of the control group, and the treatment effect is shown in Table 3.
TABLE 3 integral comparison of symptoms before and after treatment of two groups±SDividing into two parts
Note that: in comparison with the pre-treatment period of this group, △ p is less than 0.05; compared with the control group ▲ P＜0.05。
Reference is made to:
[1] wu Wenyao, zhang Jin, zheng Hua. World medical Association "Hull octyl declaration": ethical principles of medical research involving human subjects [ J ]. Journal of chinese pain, 2020, 16 (2): 42.
[2] chinese medical society. Diagnosis and treatment guide for common diseases of otorhinolaryngology department of traditional Chinese medicine [ M ]. Beijing: chinese traditional medicine press 2012.
[3] Chinese medical administration national medical science and drug industry Standard of the people's republic of China, chinese medical evidence diagnosis and treatment Standard [ M ]. Nanjing university Press, 1994:126-127.
[4] Wang De the progenitors are expected from the science of otorhinolaryngology [ M ]. Shanghai science and technology Press, 1985:83-84.
[5] Wang Shizhen the science of ear, nose, throat and throat [ M ]. 2 nd edition: chinese traditional medicine press, 2011:152-157.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, and alternatives falling within the spirit and principles of the invention.
Claims (5)
1. The traditional Chinese medicine composition for treating the chronic pharyngitis is characterized by comprising the following components in parts by mass: 14-16 parts of thunberg fritillary bulb, 8-10 parts of scorpion, 9-11 parts of radix clematidis, 14-16 parts of stir-fried mustard seed, 9-11 parts of cicada slough, 9-11 parts of lithospermum, 19-21 parts of rehmannia root, 19-21 parts of stir-fried white paeony root, 14-16 parts of perilla leaf, 9-11 parts of purified pinellia tuber, 9-11 parts of divaricate saposhnikovia root and 9-11 parts of liquorice.
2. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition comprises the following components in parts by mass: 15 parts of fritillary bulb, 9 parts of scorpion, 10 parts of radix clematidis, 15 parts of fried mustard seed, 10 parts of cicada slough, 10 parts of herba lycopodii, 20 parts of rehmannia root, 20 parts of fried white peony root, 15 parts of perilla leaf, 10 parts of purified pinellia tuber, 10 parts of divaricate saposhnikovia root and 10 parts of liquorice.
3. The use of a Chinese medicinal composition according to claim 1 or 2 for the preparation of a medicament for the treatment or alleviation of chronic pharyngitis disorders.
4. The use according to claim 3, wherein the medicament further comprises a therapeutically effective amount of a Chinese medicinal composition and a pharmaceutically acceptable carrier therefor.
5. The use according to claim 4, wherein the medicament is in the form of a powder, a pill, a tablet, a capsule, an oral liquid, an aerosol or an injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310677251.2A CN116531457A (en) | 2023-06-09 | 2023-06-09 | Traditional Chinese medicine composition for treating chronic pharyngitis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310677251.2A CN116531457A (en) | 2023-06-09 | 2023-06-09 | Traditional Chinese medicine composition for treating chronic pharyngitis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116531457A true CN116531457A (en) | 2023-08-04 |
Family
ID=87450827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310677251.2A Pending CN116531457A (en) | 2023-06-09 | 2023-06-09 | Traditional Chinese medicine composition for treating chronic pharyngitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116531457A (en) |
-
2023
- 2023-06-09 CN CN202310677251.2A patent/CN116531457A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106138360A (en) | A kind of Chinese medicine composition and preparation method thereof, application | |
| CN103099948A (en) | Pharmaceutical composition for treating pharyngitis and preparation method | |
| CN112294911A (en) | Traditional Chinese medicine composition for treating cough with lung heat | |
| CN102949524A (en) | Pure traditional Chinese medicine health-care sirup for clearing heat from throat and preparation method thereof | |
| CN113476562B (en) | Composition and preparation method and application thereof | |
| CN114767824A (en) | Preparation for treating laryngeal cough and preparation method thereof | |
| CN116531457A (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and application thereof | |
| CN102949572A (en) | Medicinal composition for treating throat diseases, and its preparation method | |
| CN105748899A (en) | Pharmaceutical preparation for treating pharyngitis and use thereof | |
| CN111481585A (en) | Pharmaceutical composition for treating chronic pharyngitis and preparation method and application thereof | |
| CN104524256A (en) | Traditional Chinese medicine for treating viral pneumonia | |
| CN104940764A (en) | Traditional Chinese medicine composition preparation for treating pulmonary tuberculosis | |
| CN114917287B (en) | Traditional Chinese medicine composition for treating allergic asthma, preparation method and application thereof | |
| CN116966232B (en) | Traditional Chinese medicine composition for treating phlegm-heat accumulated lung syndrome community-acquired pneumonia and application thereof | |
| CN115990228B (en) | Preparation method and application of traditional Chinese medicine composition for relieving pharyngitis, relieving cough and reducing sputum | |
| CN114010691B (en) | Qingyu throat-benefiting buccal tablet and preparation method thereof | |
| CN104940763A (en) | Traditional Chinese medicine preparation for treating primary pulmonary tuberculosis | |
| CN105031444A (en) | Traditional Chinese medicinal composition for treating primary tuberculosis | |
| CN116832104A (en) | Traditional Chinese medicine for relieving cough and reducing sputum | |
| CN104398889A (en) | Traditional Chinese medicine composition capable of expelling phlegm and arresting coughing and preparation method of traditional Chinese medicine composition | |
| CN118021925A (en) | Traditional Chinese medicine composition for treating intractable chronic cough | |
| CN105362548A (en) | Traditional Chinese medicine for treating allergic asthma | |
| CN104906352A (en) | Traditional Chinese medicine liquid for treating deficiency-fire flaring-up type infantile oral ulcer and preparation method thereof | |
| CN102755576B (en) | Traditional Chinese medicine spray for treating respiratory tract inflammation | |
| CN115006495A (en) | Chinese medicinal prescription for treating cough caused by virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |